Bristol Myers vets tie up another all-stock deal, lining up clinical-stage oncology pipeline
A handful of Bristol Myers Squibb vets setting up a fledgling cancer drug developer have wrapped back-to-back stock deals to create a new oncology pipeline.
Portage Biotech is helmed by CEO Ian Walters and CSO Robert Kramer, and backed by three biotech entrepreneurs — UK investor Jim Mellon, ex-Biohaven board member Declan Doogan and early Medivation backer Greg Bailey — who have whipped up a whole slate of different ventures aimed at drug development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.